Anna-Maria Hoffmann-Vold

List of Publications by Year
in descending order

70 papers	2,507 citations	218381 26 h-index	214527 47 g-index
74 all docs	74 docs citations	74 times ranked	2280 citing authors

#	Article	IF	Citations
1	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83.	2.2	182
2	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases, 2021, 80, 219-227.	0.5	160
3	Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1258-1266.	2.5	146
4	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.5	142
5	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	3.1	134
6	Predictive Value of Serial Highâ€Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 2205-2212.	2.9	124
7	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.5	120
8	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosisâ€"Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis and Rheumatology, 2017, 69, 1451-1460.	2.9	109
9	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases, 2018, 77, 1326-1332.	0.5	100
10	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	5.8	100
11	Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. Journal of the American College of Cardiology, 2018, 72, 1804-1813.	1.2	78
12	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterology, 2017, 4, e000134.	1.1	77
13	High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis. Chest, 2016, 150, 299-306.	0.4	73
14	Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease. Journal of Rheumatology, 2015, 42, 60-63.	1.0	60
15	Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Advances in Therapy, 2021, 38, 854-867.	1.3	53
16	Survival and Causes of Death in an Unselected and Complete Cohort of Norwegian Patients with Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 1127-1133.	1.0	48
17	Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial. PLoS ONE, 2020, 15, e0232739.	1.1	47
18	Nintedanib in Patients With Autoimmune Diseaseâ€"Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44

#	Article	IF	Citations
19	Endotypeâ€“phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine, 2019, 50, 379-386.	2.7	41
20	Prevalence of systemic sclerosis in south-east Norway. Rheumatology, 2012, 51, 1600-1605.	0.9	39
21	Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology, 2019, 58, 313-320.	0.9	36
22	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open, 2019, 5, e000826.	1.8	35
23	Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis. Current Opinion in Rheumatology, 2016, 28, 613-618.	2.0	33
24	The need for a holistic approach for SSc-ILD â€“ achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	1.4	33
25	Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatology, 2018, 57, 480-487.	0.9	30
26	Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Research and Therapy, 2015, 17, 231.	1.6	29
27	CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 1644-1653.	2.9	28
28	Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology, 2020, 59, 2920-2929.	0.9	28
29	Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. European Respiratory Journal, 2022, 59, 2004503.	3.1	26
30	Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS ONE, 2018, 13, e0206545.	1.1	25
31	Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort. Journal of Rheumatology, 2017, 44, 459-465.	1.0	24
32	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. Journal of Rheumatology, 2019, 46, 1316-1325.	1.0	23
33	Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Research, 2022, 8, 00597-2021.	1.1	21
34	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
35	Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110375.	1.2	19
36	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. Arthritis Research and Therapy, 2021, 23, 212.	1.6	16

#	Article	IF	Citations
37	Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. Current Opinion in Rheumatology, 2020, 32, 497-504.	2.0	15
38	Circulating biomarkers of systemic sclerosis â€“ interstitial lung disease. Journal of Scleroderma and Related Disorders, 2020, 5, 41-47.	1.0	14
39	Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders, 2021, 6, 37-43.	1.0	14
40	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 2338-2347.	2.9	14
41	Gastrointestinal tract microbiota modifications in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 228-236.	1.3	14
42	ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respiratory Research, 2020, 7, e000598.	1.2	11
43	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Research, 2021, 7, 00235-2020.	1.1	11
44	Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications. ACR Open Rheumatology, 2019, 1, 258-266.	0.9	10
45	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology, 2021, 60, 5601-5609.	0.9	10
46	The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey. Rheumatology, 2022, 61, 1459-1467.	0.9	9
47	The potential of fecal microbiota transplantation in systemic sclerosis. Expert Review of Clinical Immunology, 2020, 16, 117-118.	1.3	8
48	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 2022, 61, 1141-1147.	0.9	8
49	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open, 2021, 11, e048541.	0.8	7
50	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6
51	Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology, 2023, 62, SI43-SI53.	0.9	6
52	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology, 2020, 16, 1065-1074.	1.3	5
53	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology, 2022, 61, 743-755.	0.9	5
54	OP0064â€…EVIDENCE-BASED CONSENSUS RECOMMENDATIONS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS. , 2019, , .		4

#	Article	IF	Citations
55	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. Rheumatology, 2021, 61, 213-222.	0.9	4
56	Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 1277-1287.	2.9	4
57	Interstitial lung diseases: quo vadis?. Lancet Respiratory Medicine,the, 2021, 9, 1084-1087.	5.2	4
58	Serum markers of cardiac complications in a systemic sclerosis cohort. Scientific Reports, 2022, 12, 4661.	1.6	4
59	Longitudinal Characterisation of the Gastrointestinal Tract Microbiome in Systemic Sclerosis. European Medical Journal (Chelmsford, England), 0, , 110-118.	3.0	3
60	Dr. Hoffmann-Vold replies. Journal of Rheumatology, 2015, 42, 2513.1-2513.	1.0	2
61	Selexipag treatment in patients with systemic sclerosisâ€“associated pulmonary arterial hypertension in clinical practice, a case series. Journal of Scleroderma and Related Disorders, 2020, 5, NP7-NP11.	1.0	2
62	CCL21 as a potential biomarker for pulmonary arterial hypertension in systemic sclerosis. Arthritis and Rheumatology, 2018, 71, 655.	2.9	1
63	OP0327â€…FECAL MICROBIOTA TRANSPLANTATION IN SYSTEMIC SCLEROSIS: A DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PILOT TRIAL. , 2019, , .		1
64	OP0239â€…PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
65	Reply. Arthritis and Rheumatology, 2019, 71, 655-656.	2.9	0
66	FRI0325â€…IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€“ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
67	SAT0282â€…EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSIONIN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
68	FRI0300â€…IMPACT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS IN A COMPLETE, NATIONWIDE COHORT. , 2019, , .		0
69	One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease?. Thorax, 2021, 76, 1170-1171.	2.7	0
70	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 0, , .	0.9	0